Company intelligence / Profile preview
LifeMine Therapeutics
Cambridge, Massachusetts, United Stateslifeminetx.com ↗
- Ownership
- Private
- Employees
- ~100
- Development stage
- Other
01
Overview
First participant dosed in Phase 1 clinical trial of LIFE-001 (a novel calcineurin inhibitor) in April 2025. LIFE-001 has shown improved safety compared to legacy calcineurin inhibitors in preclinical studies, with efficacy in animal models of ulcerative colitis and Crohn's disease.
- Therapeutic areas
- GastroenterologyImmunologyInfectious Diseases
- Modalities
- Small moleculesgenetically-encoded small molecules (GEMs)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on LifeMine Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LifeMine Therapeutics.